Sun Pharma winds down JV with MSD

Sun Pharmaceutical Industries Ltd and the US-based Merck Sharp & Dohme (MSD) have decided to wind down their joint venture established in 2011, due to changes in the strategic priorities of both the parent companies. As a result of this decision, the companies established for the purpose, MSD-Sun Llc and MSD-Sun FZ Llc, will be dissolved.
 
Sun and MSD JV was established to develop, manufacture and commercialise new combinations and formulations of innovative and branded generics for emerging markets.
 
Sun Pharma and MSD will continue their collaboration for other business relationships including the strategic India-specific co-marketing partnership for sitagliptin and their licensing deal on Merck's experimental skin disease drug tildrakizumab, said Sun Pharma in a BSE filing on February 12, 2016.